Popular Articles

Obama Urges Swift Confirmation Of Sotomayor; GOP Mulls Opposition Strategy
President Obama on Tuesday in his official announcement of his nomination of Judge Sonia Sotomayor of the Second Circuit Court of Appeals to the Supreme Court emphasized what he called her "extraordinary journey" from a modest background to the top of the judiciary, launching a "confirmation battle that he hopes to wage over biography more than ideology," the New York Times reports. If confirmed, Sotomayor would be the first Hispanic and the third woman to serve on the court, as well as the sixth of the court"s current members with a Roman Catholic background, the Times reports (Baker/Zeleny, New York Times, 5/27). Sotomayor would replace retiring Justice David Souter, who typically is a liberal vote on social issues, the Wall Street Journal reports. Therefore, the addition of Sotomayor would not likely change the ideological balance of the court (Bravin/Koppel, Wall Street Journal, 5/27). The Washington Post reports Obama in his remarks cast Sotomayor "as the embodiment of the qualities he seeks in a judge," including superior intelligence, an understanding of the limited role of the judiciary and what he called "an understanding of how the world works and how ordinary people live" (Barnes/Fletcher, Washington Post, 5/27). The president said he wants Sotomayor to be confirmed before the Senate leaves in August for its summer recess, so she can join the court in time for its September review of potential cases. White House Press Secretary Robert Gibbs said that the Senate has "ample time" to complete the confirmation process, as the average time span is 72 days and there are 74 until the recess (Koffler, Roll Call, 5/26). Senate Judiciary Committee Chair Patrick Leahy (D-Vt.) praised Obama"s decision, calling Sotomayor"s record "exemplary" and her nomination "historic." Leahy noted that both former President George H.W. Bush and former President Clinton nominated Sotomayor to federal judgeships, adding, "She has been nominated by both Democratic and Republican presidents, and she was twice confirmed by the Senate with strong, bipartisan support" (Stanton, Roll Call, 5/26).Rulings on Abortion Rights Throughout her career as a federal judge, Sotomayor has not issued what are considered major decisions regarding abortion rights, although her record on cases involving civil and social rights issues appear "more liberal than not," according to the New York Times (Liptak, New York Times, 5/27). Politico reports that Sotomayor has ruled in favor of antiabortion-rights groups in two cases. The first case occurred in 2002 when she sided with the Bush administration in its efforts to implement the "global gag rule," which banned federal funding for international family planning groups that offer abortion services or information with their own funds. Sotomayor ruled that the government had the right to decide how to spend its funding. In 2004, Sotomayor ruled in favor of antiabortion-rights protesters who alleged that they were brutalized while being arrested in West Hartford, Conn. (Gerstein/Javers, Politico, 5/26). Gibbs said that Obama did not ask Sotomayor about issues related to abortion during her vetting and there was "no litmus test" on abortion-rights issues (Koffler, Roll Call, 5/26).Obama"s announcement was well-received by many groups that support abortion rights. NARAL Pro-Choice America President Nancy Keenan said the group is anticipating more information about Sotomayor"s views on abortion rights and the right to privacy. She added that the group is "encouraged by the strong support she receives from her peers and other legal scholars and the fact that the Senate has twice confirmed her for federal judgeships" (Posner, Congress Daily, 5/26). Kim Gandy, president of the National Organization of Women, said that Sotomayor "brings a lifelong commitment to equality, justice and opportunity, as well as the respect of her peers, unassailable integrity and a keen intellect informed by experience." Gandy added that Obama "said he wanted a justice with "towering intellect" and a "common to
generic viagra online
Advaxis Engages The Numoda Corporation To Oversee Phase II Clinical Trials Of ADXS11-001
Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia).
News of the day
Court Of Appeal To Re-Evaluate NICE Osteoporosis Decision, UK
Servier Laboratories Limited has been granted permission by the Court of Appeal to challenge a High Court decision made at a Judicial Review in February this year, in which Servier was previously successful in its claim that the National Institute for Health and Clinical Excellence (NICE) had unlawfully failed to provide the economic model underlying its Guidance for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. 1,2
Endocrinology

FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair

The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a possible association between patients who use Xolair and an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The study is being conducted by the manufacturer, San Francisco-based Genentech Inc. An FDA Early Communication is available online. The Early Communication is in keeping with the FDA"s commitment to inform the public about its ongoing safety reviews of drugs. Once its review is completed, the FDA will communicate its findings and any resulting recommendations to the public. Until the evaluation is completed, health care professionals and patients should be aware that the agency is reviewing data that may suggest a risk of adverse events. The FDA is not advising a change in prescribing or use of the drug. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):